Loading
Life sciences · Interventional Study
ClinicalTrials.gov · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07828483). This is a study registration, not published results. Lead sponsor: Stanford University. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 25 participants (ESTIMATED). Conditions: Post-traumatic Brain Injury Depression, Veteran Health. Interventions: DEVICE: Active Low-Intensity Focused Ultrasound (LIFU); OTHER: Sham Low-Intensity Focused Ultrasound (LIFU). Primary outcome measures: To evaluate the safety and tolerability of repeated sgACC-targeted LIFU stimulation in adult Veterans with PTD. , Baseline, Treatment Days 1 through 5, 1-Week, 1-2:4-week follow up visits.. Brief summary: The goal of this clinical trial is to learn about evaluate the safety, tolerability, and feasibility of MRI-guided LIFU targeting the sgACC in Veterans with post-traumatic brain injury depression. The main questions it aims to answer are: 1. the safety, tolerability, and feasibility of MRI-guided LIFU. 2. Evaluate preliminary antidepressant efficacy. 3. Characterize target engagement using multimodal neuroimaging and electrophysiology. 4. Identify imaging and electrophysiological biomarkers that predict treatment response. 5. Generate preliminary effect size estimates to support future multicenter clinical trials.